FPR2 and malignant colon neoplasm: The antitumor activity of RvD1 was observed to act through the inhibition of the G-protein coupled formyl peptide receptor 2 (ALX/FPR2)-mediated c-Myc expression in either TNFα-stimulated normal colon cells (Figure 3b) or colon cancer cell lines via the attenuation of NF-κB signaling and proteasomal degradation and the stimulation of resolution macrophages [121].